JPS6340200B2 - - Google Patents

Info

Publication number: JPS6340200B2
Authority: JP; Japan
Prior art keywords: cyclosporin; spectrum; formula; see; derivative
Prior art date: 1978-10-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP54134710A

Other languages

English (en)

Japanese (ja)

Other versions

JPS5555150A (en

Inventor

Pii Torabaa Rene

Hofuman Hansu

Herii Oigen

Kuun Matsukusu

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

SANDO AG

Original Assignee

SANDO AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-10-18

Filing date

1979-10-17

Publication date

1988-08-10

1979-10-17 Application filed by SANDO AG filed Critical SANDO AG

1980-04-22 Publication of JPS5555150A publication Critical patent/JPS5555150A/ja

1988-08-10 Publication of JPS6340200B2 publication Critical patent/JPS6340200B2/ja

Status Granted legal-status Critical Current

Links

ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 claims description 41
108010019249 cyclosporin G Proteins 0.000 claims description 41
ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 claims description 39
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 17
150000001875 compounds Chemical class 0.000 claims description 16
239000000203 mixture Substances 0.000 claims description 15
TYFOVYYNQGNDKH-KCLVVAEESA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-ethyl-33-[(1r)-1-hydroxy-2-methylhexyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26, Chemical compound CCCCC(C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC1=O TYFOVYYNQGNDKH-KCLVVAEESA-N 0.000 claims description 12
ZNVBEWJRWHNZMK-SYOLRUPNSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,2 Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O ZNVBEWJRWHNZMK-SYOLRUPNSA-N 0.000 claims description 11
108010019594 cyclosporin D Proteins 0.000 claims description 11
238000010521 absorption reaction Methods 0.000 claims description 10
238000002329 infrared spectrum Methods 0.000 claims description 10
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 claims description 10
239000000126 substance Substances 0.000 claims description 10
238000004519 manufacturing process Methods 0.000 claims description 9
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 claims description 9
238000002211 ultraviolet spectrum Methods 0.000 claims description 9
238000002844 melting Methods 0.000 claims description 8
230000008018 melting Effects 0.000 claims description 8
239000012086 standard solution Substances 0.000 claims description 5
235000015097 nutrients Nutrition 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
239000000843 powder Substances 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 3
230000001506 immunosuppresive effect Effects 0.000 claims description 3
239000008024 pharmaceutical diluent Substances 0.000 claims description 3
241001149964 Tolypocladium Species 0.000 claims description 2
230000003110 anti-inflammatory effect Effects 0.000 claims description 2
229930105110 Cyclosporin A Natural products 0.000 claims 3
108010036949 Cyclosporine Proteins 0.000 claims 3
229960001265 ciclosporin Drugs 0.000 claims 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
238000000034 method Methods 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
239000000741 silica gel Substances 0.000 description 7
229910002027 silica gel Inorganic materials 0.000 description 7
239000000243 solution Substances 0.000 description 6
239000003480 eluent Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
239000013078 crystal Substances 0.000 description 4
229910052763 palladium Inorganic materials 0.000 description 4
JTOKYIBTLUQVQV-QRVTZXGZSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-[(1r)-1-hydroxyethyl]-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontan Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H]([C@@H](C)O)NC1=O JTOKYIBTLUQVQV-QRVTZXGZSA-N 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
JTOKYIBTLUQVQV-UHFFFAOYSA-N Cyclosporin C Natural products CC=CCC(C)C(O)C1N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C(=O)C(C(C)O)NC1=O JTOKYIBTLUQVQV-UHFFFAOYSA-N 0.000 description 3
108010036941 Cyclosporins Proteins 0.000 description 3
241001149960 Tolypocladium inflatum Species 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000009471 action Effects 0.000 description 3
229930182912 cyclosporin Natural products 0.000 description 3
108010019248 cyclosporin C Proteins 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000003208 petroleum Substances 0.000 description 3
239000000047 product Substances 0.000 description 3
238000004809 thin layer chromatography Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
241000223259 Trichoderma Species 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
238000001035 drying Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
229940098779 methanesulfonic acid Drugs 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
239000002904 solvent Substances 0.000 description 2
230000001629 suppression Effects 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 1
239000004254 Ammonium phosphate Substances 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
108010062580 Concanavalin A Proteins 0.000 description 1
206010014025 Ear swelling Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010018910 Haemolysis Diseases 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
241000364057 Peoria Species 0.000 description 1
241000700159 Rattus Species 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
238000005273 aeration Methods 0.000 description 1
238000013019 agitation Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910000148 ammonium phosphate Inorganic materials 0.000 description 1
235000019289 ammonium phosphates Nutrition 0.000 description 1
229940040526 anhydrous sodium acetate Drugs 0.000 description 1
230000002456 anti-arthritic effect Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000008588 hemolysis Effects 0.000 description 1
230000002949 hemolytic effect Effects 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940027941 immunoglobulin g Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
239000012452 mother liquor Substances 0.000 description 1
230000035772 mutation Effects 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000012827 research and development Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
230000003393 splenic effect Effects 0.000 description 1
239000010959 steel Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
230000000153 supplemental effect Effects 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/145—Fungal isolates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C12R2001/885—Trichoderma

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Biotechnology (AREA)
General Chemical & Material Sciences (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Mycology (AREA)
Transplantation (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Botany (AREA)
Tropical Medicine & Parasitology (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

JP13471079A 1978-10-18 1979-10-17 Cyclosporin derivatives*their manufacture and medical composition containing them Granted JPS5555150A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CH1077678A CH637124A5 (en)	1978-10-18	1978-10-18	Antibiotic, its preparation and use

Publications (2)

Publication Number	Publication Date
JPS5555150A JPS5555150A (en)	1980-04-22
JPS6340200B2 true JPS6340200B2 (it)	1988-08-10

Family

ID=4366764

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP13471079A Granted JPS5555150A (en)	1978-10-18	1979-10-17	Cyclosporin derivatives*their manufacture and medical composition containing them

Country Status (5)

Country	Link
JP (1)	JPS5555150A (it)
AT (1)	AT375399B (it)
BE (1)	BE879402A (it)
CH (1)	CH637124A5 (it)
ZA (1)	ZA795560B (it)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU203564B (en) *	1987-12-21	1991-08-28	Sandoz Ag	Process for producing new orthorombos cyclosporin without solvatation
US5447854A (en) *	1991-01-25	1995-09-05	Fujisawa Pharmaceutical Co., Ltd.	Production of cyclosporin A and/or C with a strain of NECTRIA

1978
- 1978-10-18 CH CH1077678A patent/CH637124A5/de not_active IP Right Cessation
1979
- 1979-10-15 BE BE1/9567A patent/BE879402A/fr not_active IP Right Cessation
- 1979-10-16 AT AT0672679A patent/AT375399B/de not_active IP Right Cessation
- 1979-10-17 JP JP13471079A patent/JPS5555150A/ja active Granted
- 1979-10-18 ZA ZA00795560A patent/ZA795560B/xx unknown

Also Published As

Publication number	Publication date
BE879402A (fr)	1980-04-15
CH637124A5 (en)	1983-07-15
ATA672679A (de)	1983-12-15
AT375399B (de)	1984-07-25
JPS5555150A (en)	1980-04-22
ZA795560B (en)	1981-05-27

Publication	Publication Date	Title
US4288431A (en)	1981-09-08	Cyclosporin derivatives, their production and pharmaceutical compositions containing them
CA1117046A (en)	1982-01-26	Organic compounds
US4108985A (en)	1978-08-22	Dihydrocyclosporin c
US4210581A (en)	1980-07-01	Organic compounds
US3069322A (en)	1962-12-18	Pge and pgf
JPH02500738A (ja)	1990-03-15	抗腫瘍組成物およびその使用法
EA001356B1 (ru)	2001-02-26	Дигликозилированные 1,2-диолы как псевдосоединения сиалил- lewis x и сиалил-lewis a
GB1599863A (en)	1981-10-07	Pharmaceutical compositions for use in the inhibition of the biosynthesis of mevalonic acid
Solomons et al.	1974	Synthesis and antimicrobial properties of 17β‐amino‐4‐aza‐5α‐androstane and derivatives
JPS6340200B2 (it)	1988-08-10
JPH0559046A (ja)	1993-03-09	免疫調節剤
US3752800A (en)	1973-08-14	Process for the manufacture of a pyroglutamylpeptide
FI63742B (fi)	1983-04-29	Foerfarande foer framstaellning av terapeutiskt anvaendbart diydrocyklosporin
US3547911A (en)	1970-12-15	Synthesis of antheridiol and its derivatives
US4045577A (en)	1977-08-30	Valuable medicinial prostaglandin compounds prepared from material isolated from the sea
JPH0453867B2 (it)	1992-08-27
CH640265A5 (fr)	1983-12-30	Antibiotique et composition veterinaire.
JP3030896B2 (ja)	2000-04-10	Ｗｂ９６８物質群およびその製造法
US3300501A (en)	1967-01-24	6-azasteroids
US3246018A (en)	1966-04-12	3beta-aminoandrost-5-ene-17beta-carboxylic acid and derivatives thereof
JPH05271267A (ja)	1993-10-19	Ｆｒ９０１４５９物質、その製法及び用途
US3171845A (en)	1965-03-02	20-difluoro-pregnanes and methods to prepare same
JPS63264563A (ja)	1988-11-01	アミノ酸誘導体およびその製造法
JPS62270527A (ja)	1987-11-24	４１８１−２物質及びその誘導体を有効成分とする抗腫瘍剤
JPH0931088A (ja)	1997-02-04	Ｗｂ９６８物質群およびその製造法